The following is a summary of the DiaMedica Therapeutics Inc. (DMAC) Q1 2024 Earnings Call Transcript:

Financial Performance:

• DiaMedica reported total combined cash and investments of $46.5 million as of Q1 2024, and working capital of $44.9 million.

• Net cash used in operating activities for the quarter was $6.7 million.

• There was an increase in research and development expenses to $3.7 million, along with general and administrative expenses of $2.1 million.

Business Progress:

• DiaMedica is increasing its clinical trial operations with the addition of 3 experienced personnel and continues its patient enrollment at a healthy pace.

• Successful treatment of over 1 million patients with Kailikang in China in 2023 reaffirms its potential.

• The company expects a significant number of site activations for its trials in Q3 2024, with the interim analysis set for Q1 2025.

• DiaMedica is in the process of legally appealing a recent judgement against them concerning PRA.

More details: DiaMedica Therapeutics IR

Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.